| Effect of Mepolizumab on Severe Eosinophilic Asthma (NCT04641741) | Hospital Clinico Universitario de Santiago | 2021-04-01 |
| Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma (NCT05002621) | Mayo Clinic | 2021-02-16 |
| XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma (NCT04674137) | Chemlmmune Therapeutics LLC | 2020-12-16 |
| Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma (NCT04671446) | Queen Mary University of London | 2020-12-10 |
| Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma (NCT05398133) | Medical University of Warsaw | 2020-09-01 |
| Eosinophils Endotypes in Chronic Airway Inflammatory Diseases (NCT04187976) | University Hospital, Lille | 2020-03-03 |
| Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils (NCT04538937) | Medical University Innsbruck | 2020-02-26 |
| A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil (NCT04228588) | University of Sao Paulo General Hospital | 2020-01-09 |
| Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma (NCT04046939) | Knopp Biosciences | 2019-08-15 |
| Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab". (NCT04585997) | University of Newcastle, Australia | 2018-11-03 |
| Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma (NCT03563521) | TC Erciyes University | 2017-11-27 |
| Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma (NCT03469934) | AnaptysBio, Inc. | 2017-11-14 |
| Intense Airway Eosinophilia in Asthma (NCT03696914) | Laval University | 2017-06-06 |
| Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma (NCT01508936) | Teva Branded Pharmaceutical Products R&D, Inc. | 2012-02-01 |
| Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma (NCT01290887) | Teva Branded Pharmaceutical Products R&D, Inc. | 2011-06-01 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma (NCT01285323) | Teva Branded Pharmaceutical Products R&D, Inc. | 2011-03-01 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma (NCT01270464) | Teva Branded Pharmaceutical Products R&D, Inc. | 2011-02-01 |